Stay updated on Ampyra Optic Neuritis in MS Clinical Trial
Sign up to get notified when there's something new on the Ampyra Optic Neuritis in MS Clinical Trial page.

Latest updates to the Ampyra Optic Neuritis in MS Clinical Trial page
- ChecktodayChange DetectedThe ClinicalTrials.gov site revision label changes from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check7 days agoChange DetectedThe record describes a completed Phase 2 crossover study testing dalfampridine (Ampyra) for visual impairment after optic neuritis in people with multiple sclerosis. It includes study eligibility and treatment details, outcome measures, investigators, publications, and results-related record dates.SummaryDifference55%

- Check14 days agoChange DetectedThe site footer now identifies the platform as revision v3.8.0 instead of v3.7.2. The page still displays a 403 Forbidden error rather than study details.SummaryDifference0.2%

- Check28 days agoChange DetectedA banner about NIH website changes was added, and the site revision changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check42 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1; the page still displays a 403 error.SummaryDifference0.2%

- Check56 days agoChange DetectedA broad set of MeSH terms and keywords tied to the study topic were removed from the record, affecting how the study is categorized and found in searches.SummaryDifference19%

Stay in the know with updates to Ampyra Optic Neuritis in MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ampyra Optic Neuritis in MS Clinical Trial page.